Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Lung Cancer
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: The characteristics and treatment sequence of patients treated with nivolumab The effectiveness of nivolumab treatment…
- Trial name
- LIST (NCT04500535)
- Where
- France
- Volunteers
- 535 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and…
- Trial name
- REZILIENT2 (NCT05967689)
- Testing
- TAS6417, CYP Cocktail, Transporter Cocktail
- Where
- 80 sites in United States, Australia and 10 more
- Volunteers
- 220 people
- Sponsor
- Taiho Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT06282874
- Testing
- Lorlatinib
- Where
- 3 sites in China
- Volunteers
- 41 people
- Sponsor
- Guangdong Association of Clinical Trials
Prostate Cancer, Bladder Cancer
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.
- Conditions
- Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT00199849
- Testing
- NY-ESO-1 Plasmid DNA Cancer Vaccine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ludwig Institute for Cancer Research
Lung Cancer
Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268489
- Testing
- bevacizumab, pemetrexed disodium
- Where
- 248 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Non-small-cell Lung Cancer
ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer
The primary objective of this study is to examine if the combination regimen of ARQ 197 with erlotinib is active in subjects with locally advanced or metastatic NSCLC with activating mutation EGFR who progressed on EGFR-TKI…
- Trial name
- NCT01580735
- Testing
- ARQ 197
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cachexia, Fatigue
Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
This randomized clinical trial studies pulmonary rehabilitation in improving lung function in patients with locally advanced non-small cell lung cancer undergoing chemoradiation.
- Conditions
- Cachexia, Fatigue, Pulmonary Complications, Radiation Toxicity
- Trial name
- NCT02017925
- Testing
- exercise intervention, pulmonary complications management/prevention, quality-of-life assessment
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Cancer, Non-Small-Cell Lung Carcinoma
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients
This study will determine the objective response rate in chemotherapy naive non-small cell lung cancer patients with advanced disease.
- Trial name
- NCT00201825
- Testing
- Capecitabine, Docetaxel
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Tony Bekaii-Saab
Lung Cancer
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00028925
- Testing
- filgrastim, carboplatin, topotecan hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00388089
- Testing
- bortezomib, topotecan hydrochloride, flow cytometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Davis
Non-Small Cell Lung Cancer
Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
The study aims at piloting the concept of customization of chemotherapy based on molecular markers in patients with stage IIIB (with pleural effusion) and IV with performance status ≤ 2 with pathologically proven non-small cell…
- Trial name
- Customizing (NCT01356368)
- Testing
- Cisplatin, Gemzar, Docetaxel, Alimta
- Where
- Saudi Arabia
- Volunteers
- 3 people
- Sponsor
- National Guard Health Affairs
Non-Small Cell Lung Cancer
68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
The purpose of this study is to explore the effectiveness of 68Ga-grazytracer PET/CT in early evaluation of neoadjuvant immunotherapy response in resectable NSCLC.
- Trial name
- NCT06756217
- Testing
- 68Ga-grazytracer PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer Metastatic, EGFR G719X
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.
- Conditions
- Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
- Trial name
- IcomBine (NCT06517953)
- Testing
- Icotinib, Befotertinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sun Yat-sen University
Small Cell Lung Cancer Extensive Stage, Brain Metastases
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
- Conditions
- Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer
- Trial name
- PRISM (NCT07139990)
- Testing
- Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Advanced Malignancy, Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT02437916
- Testing
- AMG 228
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Amgen
NSCLC
The Efficacy and Safety of KN046 Combined With Axitinib
Evaluation of the efficacy of KN046 combined with acitinib as a neoadjuvant therapy for resectable NSCLC through primary pathological response rate and surgical resection rate
- Trial name
- NCT06020352
- Testing
- KN046 plus Axitinib
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Lung Cancer
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer
This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.
- Trial name
- NCT00193349
- Testing
- Imatinib, Irinotecan, Carboplatin
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.